Amgen reported stronger-than-expected second-quarter results, with revenue rising 9% from a year earlier to $9.18 billion, topping the $8.91 billion average analyst estimate. Adjusted earnings climbed 21% to $6.02 a share, beating projections of $5.26, while GAAP earnings almost doubled to $2.65. Product sales also advanced 9% to $8.77 billion as 15 medicines, including Repatha, Evenity and Tezspire, generated double-digit growth that offset price pressure on Prolia and Enbrel. Buoyed by the performance, the biotechnology company lifted its full-year outlook. Amgen now expects 2025 revenue of $35 billion to $36 billion, up from $34.3 billion to $35.7 billion previously, and sees adjusted earnings of $20.20 to $21.30 a share, versus an earlier range of $20.00 to $21.20. The forecast incorporates the impact of the U.S. 145% tariff on Chinese goods that took effect in April. Operating cash generation remained robust, producing $1.9 billion of free cash flow in the quarter. Amgen retired $1.4 billion of debt, ending June with $8.0 billion in cash against $56.2 billion in borrowings, and paid a dividend of $2.38 per share. Management said continued investment in late-stage programs such as MariTide and Imdelltra should sustain long-term growth even as some flagship products face biosimilar competition later this year.